Paris, France, November 7, 2019 – Servier, an independent international pharmaceutical company, today announced that it will present pre-clinical data supporting UCART19 during the 61st American Society of Hematology (ASH) Annual Meeting & Exposition taking place December 7 – 10 at the Orange County Convention Center (OCCC) in Orlando, FL.
UCART19, sponsored by Servier, is in Phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).
The ASH abstract is now available at www.hematology.org.
Session: 703. Adoptive Immunotherapy: Mechanisms and New Approaches: Poster II
Title: Allogeneic Anti-CD19 CAR T Cells Manufactured from Healthy Donors Provide a Unique Cellular Product with Distinct Phenotypic Characteristics Compared to CAR T Cells Generated from Patients with Mature B Cell Malignancies
Presenter: Charlotte Graham, MRCP, FRCPath, King’s College Hospital, London
Session Date & Time: Sunday, December 8, 2019; 6 – 8 p.m.
Location: Orange County Convention Center, Hall B
UCART19 is being jointly developed under a clinical development collaboration between Servier and Allogene based on an exclusive license granted by Cellectis to Servier. UCART19 utilizes TALEN® gene-editing technology pioneered and owned by Cellectis. Servier grants to Allogene exclusive rights to UCART19 in the U.S. while Servier retains exclusive rights for all other countries.